We recently compiled a list of the Top 10 Small-Cap Stocks with Highest Upside Potential. In this article, we are going to take a look at where Allogene Therapeutics, Inc. (NASDAQ:ALLO) stands against the other small-cap stocks.
Small-cap stocks are companies with a market capitalization of somewhere between $250 million and $2 billion. They are usually the new and the world’s up-and-coming companies.
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors that took the risk with proper research and analysis reap the profits.
As mentioned in one of our previous articles i.e. 8 best small-cap stocks according to analysts, a report from Julius Baer, a private banking company based in Zurich, explains how small-cap stocks have proved to outperform over very long periods. The report states that a single dollar invested in the US large caps in 1926 grew in value to $5,767 by the end of 2018. But, a dollar invested in small caps would have been worth almost seven times more at $38,842.
As with anything else, investing in small-cap stocks comes with its benefits and drawbacks. Small-cap companies have a high potential for growth and their shares aren’t necessarily too expensive, investors can make a lot of profit with the rapid growth in share prices of these up-and-coming companies. Moreover, according to a recent analysis posted by MorningStar, Small caps look cheaper now relative to the broad market than at any time in the last 20 years. But these high returns often come with high risk, small-cap stocks are vulnerable to economic fluctuations because they don’t possess the financial power and stability as the large-cap companies.
A smart investor maintains a portfolio of several small-cap stocks with rapid growth potential and some large-cap stocks for their stability against market fluctuations. Small-cap stocks are gaining popularity among Wall Street analysts in 2024 especially in the healthcare sector because of their new therapeutic innovation and high-returns potential.
J.P. Morgan Asset Management’s Long-Term Capital Market Assumptions (LTCMAs) expect the US large-cap stocks to generate a +7.0% annualized return over the next 10 to 15 years compared to the +7.6% annualized returns expected for the mid-cap and small-cap. The private bank believes that building a portfolio of attractively valued, high-quality small-cap stocks can generate potent long-term returns while mitigating some risks.
According to Thomas Lee, the head of research and the co-founder of Fundstrat Global Advisors, there is a 50% upside for small-cap stocks in 2024. Lee stated, “You may be surprised, but small-caps have a faster revenue growth. Lee also highlighted the small-caps’ earnings growth potential, projecting a 19% growth in EPS, outpacing the S&P 500’s 12% projected YoY EPS growth for 2024.
Moreover, the Fundstrat’s CEO pointed out that the institutional investors have been dumping the small caps lately, making them ripe for a turnaround trade. Lee indicated that the current conditions of small-cap stocks are shaping up to be a mirror image of the situation in 1999 when the sector went on a streak of outperformance that lasted more than a decade. “In 1999, this was also the same launch point for 12 years of outperformance. From 1999 to 2011, small caps outperformed by 650bp annually and a cumulative 113%.”
Warren Buffet while discussing small-cap stocks said:
“If I was running $1 million today, or $10 million for that matter, I’d be fully invested. The highest rates of return I’ve ever achieved were in the 1950s. I killed the Dow. You ought to see the numbers. But I was investing peanuts then. It’s a huge structural advantage not to have a lot of money. I think I could make you 50 percent a year on $1 million. The universe I can’t play in has become more attractive than the universe I can play in. I have to look for elephants. It may be that the elephants are not as attractive as the mosquitoes. But that is the universe I must live in.”
As of June 2024, almost 1600 small-cap stocks are being traded in the US stock exchanges, so to help our readers diversify their portfolios, we have filtered out the top 10 small-cap stocks with upside potential.
Methodology
To collect data for this article, we used a stock screener and filtered the stocks with the current market cap between $250 million and $2 billion. To shortlist these 10 stocks, we took the small-cap stocks with an upside potential of over 50% backed by at least 11 or more Wall Street analysts’ price targets as of June 15th, 2024, and ranked them accordingly. Here are the top 10 small-cap stocks to buy according to analysts.
A biotechnologist in a laboratory testing an Immuno-oncology treatment.
Allogene Therapeutics, Inc. (NASDAQ:ALLO)
Upside potential as of June 15th, 2024: 451.59%
Market Cap: $490.64 million
Founded in 2017, Allogenic Therapeutics, Inc (NASDAQ:ALLO) is a clinical-stage immuno-oncology company focused on the development and commercialization of genetically engineered T-cell therapies for treating certain blood cancers and other tumors.
The analysts are very bullish about the potential of the San Francisco-based company, maintaining a “Buy” rating for the ALLO stock. This bullish view is partly because the Medical, Biomedical, and Genetics industries are seeing solid earning estimates, and often a rising tide will lift all the boats in an industry. Allogene Therapeutics is looking good on its own, with current estimates narrowing loss per share from $2.09 of the previous year to $1.52 by the end of 2024, indicating financial resilience and potential for growth.
Moreover, Allogene is set to initiate the first T-cell therapy targeting Large B-cell Lymphoma, representing innovation and leadership in the field of CAR-T therapy. Meanwhile, the acquisition of EU and UK rights for the Cema-cel expands the company’s market potential exponentially, increasing future revenue prospects.
The 12 analysts with 12-month precise forecasts for the ALLO stock have an average price target of $12.96, with a low estimate of $4.60 and a high estimate of $35. The average price target represents an upside potential of 451.49% from the current stock price of $2.35 making it the top small-cap stock to buy according to analysts.
By the end of Q1 of 2024, shares of Allogenic Therapeutics, Inc (NASDAQ:ALLO) were held by 18 hedge funds with Citadel Investment Group holding the largest stake of 3,113,225 shares valued at $13.916 million.
Overall ALLO ranks 1st on our list of the best small-cap stocks to buy. You can visit Top 10 Small-Cap Stocks with Highest Upside Potential to see the other small-cap stocks that are on hedge funds’ radar. While we acknowledge the potential of ALLO as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ALLO but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: Analyst Sees a New $25 Billion “Opportunity” for NVIDIA and Jim Cramer is Recommending These 10 Stocks in June.
Disclosure: None. This article is originally published at Insider Monkey.
